You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm shipped research-use-only tests last week to key customers to validate the assay design using clinical samples.
GenMark announced on Monday that it has begun shipping its first research-use-only tests for the novel coronavirus and intends to seek emergency use authorization.
More than 70 percent of ePlex analyzer placements in the fourth quarter were within labs that previously had a competitive analyzer, the firm said.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.
Of the 28 companies in the index, 16 companies' share prices increased while the share values of 12 declined month over month.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
Though the firm's top-line figures fell just shy of analysts' estimates, its installed base of ePlex analyzers grew 49 percent year over year.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.